Elo

Quick links to important sections

Medically reviewed

Marina Burgos

Last updated on 22/12/2025

This page provides general, reference-level information compiled from official medical sources. It is not a substitute for professional medical advice, diagnosis, or treatment. For decisions about your health, please consult a qualified healthcare professional.

Overview of Elo

This foundational section defines the medicine Elo based on its identity, composition, and pharmacological classification, strictly excluding details on dosage, usage, or safety information.

Property Description
Active Ingredient Loratadine
Form Tablet, Oral Solution (Syrup)
Pharmacological Class Second-Generation Antihistamine
Common Use Symptomatic Relief from Allergy
Origin Synthetic

What Type of Medicine is Elo?

Elo is a synthetic antihistamine medication classified as a second-generation H1-receptor antagonist, used for the general relief of symptoms associated with allergic responses. Its active ingredient is Loratadine, a chemically distinct compound that belongs to the piperidine derivative family. This specific pharmacological class is characterized by its high peripheral selectivity, meaning the compound primarily targets receptors located outside the central nervous system. This feature provides the key benefit of providing effective anti-allergic action while significantly reducing the likelihood of causing central effects, such as the sedation common to older antihistamines. This low-sedating profile is a characteristic that distinguishes it from previous antihistamine generations.


Composition and General Purpose of Elo

The medicine is supplied as a single-ingredient product, focusing exclusively on the activity of Loratadine. Elo is designed for the oral route of administration, available in common pharmaceutical preparations such as a tablet and a liquid oral solution (syrup). This range of forms allows for flexibility, particularly offering the syrup form for pediatric patients or individuals who prefer liquid intake. The general therapeutic purpose of Elo is to provide long-acting symptomatic control by blocking the action of histamine, the natural molecule that mediates the body's allergic response. A typical, neutral use scenario involves taking Elo to manage the discomfort associated with seasonal pollen exposure. Loratadine is used for managing allergic manifestations, reflecting the drug's therapeutic application in addressing common allergy discomfort.

What side effects are possible with Elo?

Possible Side Effects and Safety Information for Elo

Side effects documented in regulatory labeling for Elo (referencing approved elagolix and elotuzumab products) vary based on the specific formulation and therapeutic context. Patients should be aware of both common and serious adverse reactions.

Key Adverse Reactions

Classification Common Examples Serious/Clinically Significant Reactions
Elagolix (Oral) Hot flashes, headache, nausea, night sweats, joint pain, mood changes, anxiety. Bone mineral density (BMD) loss, suicidal ideation/behavior, severe mood disorders, and liver enzyme elevations (hepatotoxicity).
Elotuzumab (Injectable) Fatigue, diarrhea, fever, cough, constipation, peripheral neuropathy (tingling/numbness in hands/feet), upper respiratory tract infection. Infusion reactions, infections (e.g., pneumonia), second primary malignancies, liver injury, and acute renal failure.

Safety Considerations

Bone Mineral Density (BMD) Loss (Elagolix): BMD loss is a dose- and time-dependent effect. Due to this risk, specific daily doses of elagolix have mandatory maximum treatment durations (e.g., 12 months for the lower dose, 6 months for the higher dose).

Hepatic Function: Both formulations carry a risk of liver injury. Elagolix is contraindicated in women with severe hepatic impairment, and its dose is limited in moderate hepatic impairment. Patients should be monitored for signs of liver problems.

Mood Disorders: Suicidal ideation, suicidal behavior, and worsening of depression have been reported with elagolix. Patients with a history of depression may be at higher risk and require close monitoring.

Pregnancy and Contraception: Elagolix is contraindicated in pregnancy due to the risk of early pregnancy loss. Women who can become pregnant must use non-estrogen containing methods of contraception during and for a period after treatment. Elotuzumab, often administered with other agents, also necessitates the use of effective contraception.

Infusion Reactions (Elotuzumab): Infusion reactions can occur during the injection or within 24 hours afterward, potentially including fever, chills, dizziness, and shortness of breath. Premedication is often administered to mitigate this risk.

Overdose and Emergency Response

Overdose and When to Seek Help

The official regulatory documentation for Elo (Loratadine) describes specific clinical manifestations and mandated actions in the event of overdosage.

Documented Overdose Presentations

Overdose may present with systemic effects, including central nervous system (CNS) and cardiovascular signs. Officially documented manifestations include somnolence (drowsiness), tachycardia (rapid heartbeat), and headache. Increased occurrence of anticholinergic symptoms has also been reported in regulatory sources. In pediatric cases involving the syrup formulation, specific symptoms such as extrapyramidal signs and palpitations have been noted following exposure to doses greater than 10 mg.

Required Emergency Actions

Government guidance requires that individuals seek immediate medical help or contact a Poison Control Center right away in case of overdose. General symptomatic and supportive measures must be instituted promptly and maintained. Established supportive procedures mentioned in regulatory labels include the administration of activated charcoal, consideration of gastric lavage with normal saline, and the use of saline cathartics. Loratadine is not eliminated by hemodialysis.

Monitoring and Population Notes

The patient must remain under medical supervision or continuous medical monitoring after initial emergency treatment. There are specific population considerations, with increased somnolence noted for geriatric patients and individuals with hepatic or renal impairment.

Therapeutic Uses of Elo

What Elo Treats: Main Uses and Benefits

Elo is commonly used to provide supportive symptomatic relief across key domains of allergic disease and may assist with managing challenging manifestations and supporting comfort.

Alleviating Oculonasal Symptoms

This domain is relevant for managing symptoms of allergic rhinitis (hay fever), which may be seasonal or perennial. Elo may be relevant for helping ease the typical cluster of symptoms, including bothersome sneezing, a runny nose, itching of the nose and throat, and the corresponding itchy, watery eyes. The use helps address groups of symptoms that may appear suddenly and interfere with daily comfort. A key therapeutic benefit is contributing to improved comfort during periods of heightened symptoms and may assist with maintaining functional stability.

Controlling Chronic and Acute Skin Manifestations

Elo is commonly used to help with managing symptoms associated with allergic dermatologic conditions, most notably urticaria (hives). It is applied to address the highly distressing cutaneous symptoms, and may assist with managing the intense itching (pruritus) and helping to ease the accompanying redness and swelling. This application is relevant in situations involving recurrent or episodic manifestations and supports general well-being during symptomatic phases, such as in cases of Chronic Idiopathic Urticaria.


Quick Fact: Used for Managing Oculonasal and Cutaneous Symptoms

Regulatory References

  1. NIH MedlinePlus overview

Eligibility and Restrictions for Use

Elo’s population eligibility is strictly defined by government regulatory documents based on age, hypersensitivity, and organ function status. The medicine is contraindicated for individuals with a known history of allergy or hypersensitivity to the active ingredient, Loratadine, or any of its formulation components.

Age-Related Eligibility

Use is established for adults and children aged 2 years and older. Safety and effectiveness are not established for infants under 2 years of age, representing a formal regulatory exclusion for this age group.

Conditional Use Status

Specific restrictions apply based on the patient's physiological condition. Individuals with severe hepatic impairment (severe liver disease) or severe renal impairment ( GFR < 30 mL/ min) require conditional use, often involving a mandatory adjustment to a lower initial dose, as clearance of the drug may be reduced.

Special Populations

Regulatory labeling for pregnant and lactating women advises professional consultation before use, as Loratadine is known to be excreted into breast milk. Additionally, patients diagnosed with Phenylketonuria (PKU) must avoid specific oral formulations that contain the excipient phenylalanine.

What should I know about interactions with other medicines?

The medicinal product Elo is often composed of a combination of ingredients, such as an antihistamine (like levocetirizine) and a leukotriene receptor antagonist (like montelukast), which is frequently used for managing allergic conditions.

Potential Drug-Drug Interactions

When Elo is a combination product containing levocetirizine and montelukast, clinical studies have generally found a low risk of hazardous interactions with other common medicines. However, caution and monitoring are advised when co-administering Elo with certain classes of products:

  • Central Nervous System (CNS) Depressants and Alcohol: Elo's levocetirizine component can cause drowsiness. Concomitant use with alcohol or other CNS depressants, such as sedatives or anxiolytics, may amplify effects like reduced alertness, impaired psychomotor performance, and increased sedation.
  • Medicines Affecting Hepatic Enzymes (CYP450): The metabolism of one of Elo's components may be influenced by medicines that inhibit certain liver enzymes, particularly Cytochrome P450 (CYP) enzymes, such as CYP3A4 and CYP2D6. This may lead to elevated plasma concentrations of either drug, potentially increasing the risk of adverse effects. While drugs like cimetidine, erythromycin, and ketoconazole have been shown to increase the serum concentration of the antihistamine component, no clinically significant adverse events are typically reported.
  • Pain Relievers (NSAIDs): When Elo is used by patients with asthma, caution is noted regarding concomitant use with aspirin or other non-steroidal anti-inflammatory drugs (NSAIDs) as they can increase the risk of asthma exacerbation in sensitive individuals.

Interaction Classification and Context

Overall, the known interaction profile for the Elo combination product focuses on pharmacodynamic and minor pharmacokinetic interactions. The interaction relevance is generally categorized as Use with Caution/Monitoring Required rather than contraindicated, particularly when managing CNS effects or co-prescribing with known enzyme inhibitors. There are no reports of a full contraindication related to specific drug combinations.

Mechanism of Action

Selective Action on Peripheral Histamine H1-Receptors

Elo's core mechanism involves its active components, Loratadine and its metabolite, acting as selective competitive antagonists at the peripheral Histamine H1-Receptors. By binding to these receptors outside the brain, the drug directly prevents histamine from engaging its primary signaling pathway, which is initiated upon mediator release. This selective action is the basis for its sustained H1-receptor antagonism and its minimal central nervous system penetration.


Alteration of Vascular Stability and Sensory Nerves

The primary consequence of H1-receptor blockade is the alteration of specific physiological responses. This mechanism stabilizes microvascular permeability to limit the extravasation of fluid and proteins into tissues. Simultaneously, the blockade dampens the activation of peripheral sensory nerve endings, which are responsible for initiating pruritic signals. The combined action on vascular and nerve pathways constitutes the drug's total pharmacodynamic activity.

Dosage and Administration Information

Elo is administered exclusively by the oral route, aligning with its available forms: the standard 10 mg tablet, the oral solution, and the orally disintegrating tablet (ODT). For most individuals, the standard regimen involves taking 10 mg once every 24 hours. The long duration of action supports this once-daily frequency, ensuring a consistent schedule.

Administration is flexible and can be performed independent of mealtimes, as the medicine may be taken with or without food. For children between the ages of 2 and 5 years, the dose is 5 mg once daily, often administered via the oral solution using a calibrated measuring device for accuracy.

A key procedural rule requires that Elo be discontinued for at least 48 hours prior to undergoing allergy skin testing, as its presence may interfere with test results. Furthermore, specific adjustments to the standard 10 mg dose are applied for patients with reduced drug clearance. For adults and children over 6 years with severe hepatic (liver) or renal (kidney) impairment, the protocol involves administering the 10 mg dose every other day instead of daily. This modification in dosing frequency ensures reduced exposure in populations with compromised organ function. The standard use protocol follows these specific administration parameters.

Recent Clinical Evidence

Research Evidence / Overview of Studies for Elo

Evidence for Use in Allergic Rhinitis (Hay Fever)

Research for the active ingredient in Elo (Loratadine) was studied for allergic rhinitis, which involves symptoms like sneezing, runny nose, and itching of the eyes and nose. Evidence is primarily derived from numerous Randomized Controlled Trials (RCTs) across short- to medium-term durations. Researchers monitored outcomes using standardized measures like the Total Nasal Symptom Score and the Total Ocular Symptom Score, which capture changes in symptoms and physical discomfort. Findings describe patterns observed in the studies across adult, adolescent, and pediatric populations (children aged two and up).

However, research consistently describes that limited change was observed in measures related to nasal congestion when compared to the measurements for symptoms like sneezing and itching. Furthermore, some large-scale reviews and comparisons have suggested that findings were mixed when comparing the active ingredient's profile against certain other, newer antihistamines. There is also limited information for long-term outcomes regarding the sustained consistency of findings beyond several months, as follow-up durations in the main efficacy trials were limited.


Evidence for Use in Chronic Urticaria (Hives)

Studies focused on the role of the active ingredient in Chronic Idiopathic Urticaria (CIU), a condition characterized by fluctuating or episodic manifestations of hives and intense itching. The evidence comes from controlled clinical trials that monitored changes related to physical discomfort over defined time intervals. Clinical trials monitored measurements of pruritus and wheal frequency across typical short- to medium-term study durations (e.g., 4 weeks), reporting how these symptoms evolved in the observed populations.

What remains uncertain is the evidence related to modifying the standard therapeutic approach. There is limited information from large-scale studies specifically for patients whose symptoms were not fully addressed by the standard dose, meaning comparative evidence regarding higher-than-standard dosing strategies is lacking.


Studies in Special Populations

Research has explored the study of Elo's active ingredient in various populations. Studies monitored the effects in pediatric patients, with data available for children as young as two years old, where researchers examined how children reported their experience of allergic rhinitis and urticaria symptoms. For other groups, such as older adults or individuals with specific comorbidities, data remain insufficient or were generally excluded from the primary efficacy trials.

Key Studies & References

  1. Loratadine Drug Information (MedlinePlus)

Frequently Asked Questions (FAQ)

Common questions about Elo (FAQ)

Q: Is Elo considered a new drug or has it been around for a while?

A: The active ingredient in Elo, Loratadine, is a well-established medication. It is classified as a second-generation antihistamine, a specific type of drug approved for use against allergies. Official regulatory records indicate that the drug has been available and in established use for several decades.


Q: What is the difference between an allergy to Elo and a common side effect?

A: Regulatory documents categorize adverse reactions into common side effects, like headache or drowsiness, and serious allergic reactions. Allergic or hypersensitivity reactions are rare but require immediate attention and can involve symptoms such as swelling, hives, or trouble breathing. The differences between these reactions are described for clarity in the official product information.


Q: Does taking Elo affect your ability to drive or operate machinery?

A: Elo is generally recognized as a low-sedating antihistamine. However, official regulatory information indicates that some individuals may experience side effects such as drowsiness or dizziness. Because of this possibility, regulatory documents describe that caution may be warranted when performing activities that require full mental alertness, such as driving or operating machinery.


Q: Can I take Elo if I am pregnant or breastfeeding?

A: Official safety information notes that use during pregnancy or while breastfeeding is subject to consultation with a healthcare professional before use. The regulatory documents note that the active ingredient, Loratadine, is known to be excreted into breast milk.


Q: Is there a generic version of Elo available?

A: Yes, the active ingredient in Elo, which is Loratadine, is widely available in generic forms. These generic versions are approved by regulatory bodies, which require them to meet established quality and effectiveness standards consistent with the original product.


Q: Why is Elo prescribed to so many people?

A: Elo has an established role in providing symptomatic relief from common allergic conditions. Regulatory documents highlight its profile as a second-generation antihistamine that is less likely to cause central nervous system effects, such as strong sedation. This profile contributes to its broad availability and use for managing seasonal or environmental allergy symptoms.


Q: How long does it usually take to feel the effects of Elo?

A: According to clinical studies cited in the official labeling, the effects that block histamine (antihistaminic effect) generally begin within 1 to 3 hours after the medicine is taken. Maximum effect is described in studies as generally being observed at around 8 to 12 hours.


Q: Do you have to take Elo forever, or is it a short-term treatment?

A: The approach to taking this medication is typically determined by the nature of the symptoms being treated. Authoritative treatment guidelines often suggest limiting the duration of use to as short as possible, which aligns with its use for managing acute or seasonal allergic symptoms as they occur.


Q: What are the most common reasons someone would stop using Elo?

A: Discontinuation is often related to the status of the allergic symptoms being treated. Authoritative guides indicate that reasons for stopping may include symptoms resolving, experiencing a bothersome adverse effect, or decisions based on patient and prescriber preference during treatment review.


Q: Does Elo interact with common pain relievers like Tylenol or Advil?

A: The active ingredient in this medication is generally described in official sources as being able to be taken with common, non-prescription pain relievers. This includes products containing acetaminophen (Tylenol) or ibuprofen (Advil).


Q: Is Elo related to other drugs that treat similar conditions?

A: Yes, Elo belongs to the specific pharmacological class known as second-generation H1-receptor antagonists. This classification distinguishes it from first-generation antihistamines, which may have a higher likelihood of causing drowsiness, and other different classes of allergy treatments.


Q: Is Elo a controlled substance?

A: No, the active ingredient in Elo, Loratadine, is not classified as a controlled substance. It is not listed in any of the schedules (I through V) under the U.S. Controlled Substances Act (CSA) or similar regulatory frameworks in other countries.


Q: Is it true that Elo can make you gain weight?

A: Official safety data indicates that weight gain has been noted as an adverse event during post-marketing surveillance. This is described as a rare occurrence, meaning it happens infrequently among the general population using the medicine, and the exact frequency is generally not known.


Q: Can I take vitamins or herbal supplements while using Elo?

A: Due to limited studies on the combined use of this medicine with all supplements, official government health services suggest that information regarding any vitamins or herbal products being taken be shared with a healthcare professional. This is particularly relevant if the supplement is known to cause effects like drowsiness or dry mouth.


Q: What if I'm already taking medicine for my blood pressure; is that an interaction?

A: The official prescribing information for the single-ingredient product does not typically list blood pressure medicines as a specific, contraindicated interaction. However, patients with underlying heart disease or high blood pressure are generally referred in patient information materials to their healthcare professional regarding their specific circumstances.


Q: Does Elo make people sleepy or cause insomnia?

A: Official safety data indicates that both somnolence (drowsiness) and insomnia (difficulty sleeping) have been reported as possible adverse effects. The likelihood of experiencing these effects is documented in the full safety information provided by regulatory bodies.


Q: Is Elo available over the counter?

A: Yes, the medication containing the active ingredient, Loratadine, has been widely approved and is often marketed for Over-The-Counter (OTC) use. This means it can be purchased without needing a prescription from a healthcare professional.


Q: Is it true that Elo requires regular blood tests?

A: For the standard treatment of allergic symptoms, mandatory, routine blood tests are typically not required for most patients using this medication. While laboratory testing is performed during clinical trials, periodic monitoring is not a standard requirement for general use.


Q: Does Elo cause hair loss?

A: Official post-marketing safety data includes reports of alopecia, which is the medical term for hair loss. This is described as a rare event that occurred spontaneously, meaning the connection is reported through observation rather than formal clinical studies.


Q: Can you be allergic to the inactive ingredients in Elo?

A: Yes, official regulatory documents state that the medicine is contraindicated if a person has a known history of hypersensitivity or allergy. This includes not only the active ingredient (Loratadine) but also any of the other components used in the formulation of the tablet or liquid solution.


Q: What are the signs that Elo might not be working for someone?

A: Patient information guidelines indicate that signs the medication may not be providing sufficient relief include if the symptoms you are treating do not improve or if those symptoms unexpectedly worsen. This suggests the need for re-evaluation of the treatment plan.

How should Elo be stored and disposed of?

Storage and Disposal Requirements

Elo (Loratadine) must be stored strictly according to the conditions defined in its official regulatory labeling.

Storage Classification Official Requirement
Temperature Store at controlled room temperature, typically 20 C to 25 C (68 F to 77 F).
Protection Keep the medicine protected from excessive moisture and away from heat. Do not freeze the oral solution.
Child Safety Keep out of the sight and reach of children to prevent accidental ingestion.
Packaging Store in the original container to maintain integrity; tablet blister packs should remain sealed until use.

Disposal Instructions

Unused or expired Elo should be disposed of using a drug take-back program if available. If a take-back option is not accessible, the product must be mixed with an undesirable substance (e.g., used coffee grounds), sealed in a bag or container, and placed in the household trash. The medicine must not be flushed down the toilet or poured into a sink unless specifically directed by the product label.

Attention! Always consult to a doctor or pharmacist before using pills or medicines.

Available in countries:

Equivalent of Elo found in:

A-Z Index: